Increased regulatory hurdles in Europe and China could mean more medical device development focusing on the US market first. That seemed to be a major takeaway from panels on regulation and reimbursement at Healthegy's recent Medtech Conference in Minneapolis. "We're actually going to be doing more early clinical work with the FDA," said Stacey Pugh, vice president and general manager of neurovascular at Medtronic. Add to the flux the shift in the US and other countries toward making health care more value-based -- in other words, more efficient and effective. Read the story.
Why US first may be the new medical device development strategy
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.